SCHEMBL2299426

SCHEMBL2299426

Cn1c(O)nc2ncc(Cl)c(-c3ccc(F)cc3)c21

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.34
KMT2A Q03164 4/20 0.34
MET P08581 3/20 0.34
RAB9A P51151 2/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
NR3C1 P04150 2/20 0.33
PTGS2 P35354 1/20 0.33
NPC1 O15118 1/20 0.33
CYP1A2 P05177 2/20 0.32
CYP3A4 P08684 1/20 0.32
HSD17B10 Q99714 1/20 0.32
USP7 Q93009 1/20 0.32
MAPK14 Q16539 1/20 0.32
RPS6KA3 P51812 1/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
DPP4 P27487 1/20 0.32
PGR P06401 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297842 0.85 GLA (0.39) MEN1KMT2AMETRAB9AMAPT
SCHEMBL2297839 0.83 ACLY (0.37) MEN1KMT2AMETRAB9ANR3C1
SCHEMBL2297815 0.83 MEN1 (0.33) MEN1KMT2AMETRAB9AMAPT
SCHEMBL2299443 0.81 TLR8 (0.38) MAPTPGRKDM4EGCGR
SCHEMBL2299439 0.80 MET (0.33) MEN1KMT2AMETRAB9AMAPT
SCHEMBL2298084 0.80 MAPK14 (0.36) MEN1KMT2AMETRAB9AMAPT
SCHEMBL2301079 0.79 MET (0.33) MEN1KMT2AMETRAB9AMAPT
SCHEMBL2298547 0.79 GCGR (0.34) MEN1KMT2AMETRAB9AUSP7
SCHEMBL2298510 0.79 MET (0.34) MEN1KMT2AMETRAB9ANR3C1
SCHEMBL2301732 0.78 MET (0.32) MEN1KMT2AMETRAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US claimed
EP-2244711-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-11-03 EP claimed
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED 2009-10-08 US claimed
WO-2009099594-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2009-08-13 WO claimed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
US-7989469-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED (US) 2011-08-02 US disclosed
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TNNC1, TNNI3, TNNT2 MEN1 2273/4885KMT2A 3986/4885MET 3400/4885
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS TNNC1, TNNI3, TNNT2 MEN1 2615/4885KMT2A 4071/4885MET 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.